Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy

Abstract

About

This paper, published in 1950, received 590 indexed citations. Written by Masanori Asakura, Masafumi Kitakaze, Seiji Takashima, Yulin Liao, Fuminobu Ishikura, Hiroshi Ohmoto, Koichi Node, Kiyoshi Yoshino, Hiroshi Ishiguro and Hiroshi Asanuma covering the research area of Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. It is primarily cited by scholars working on Molecular Biology (350 citations), Oncology (224 citations) and Immunology and Allergy (141 citations). Published in Nature Medicine.

In The Last Decade

doi.org/10.1038/nm0102-35 →

Countries where authors are citing Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy

Since Specialization

Citations

This map shows the geographic impact of Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy more than expected).

Fields of papers citing Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1038/nm0102-35.

Explore hit-papers with similar magnitude of impact

Breakdown of academic impact, for the paper Identifying specificity groups in the T cell receptor repertoire Breakdown of academic impact, for the paper The emotional intelligence of leaders Breakdown of academic impact, for the paper Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species Breakdown of academic impact, for the paper Weight Bias among Health Professionals Specializing in Obesity Breakdown of academic impact, for the paper Blended Learning Environments: Definitions and Directions. Breakdown of academic impact, for the paper Activation of the Opioidergic Descending Pain Control System Underlies Placebo Analgesia Breakdown of academic impact, for the paper Dynamic cross-frequency couplings of local field potential oscillations in rat striatum and hippocampus during performance of a T-maze task Breakdown of academic impact, for the paper The primacy model: A new model of immediate serial recall.